Fermbox and Dyadic Launch 1st Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)
Commercial launch: Recombinant DNase 1 (RNase-free). Produced under the expanded Fermbox Bio × Dyadic collaboration, this animal-origin-free recombinant enzyme is now available in research grade. For commercial enquiries, connect with us.
Our animal-origin free recombinant proteins and enzymes portfolio, developed with Dyadic, augments Fermbox’s strategy of developing products that balance commercial scale with strong margin potential.”
BENGALURU, KARNATAKA, INDIA, March 4, 2026 /EINPresswire.com/ -- Fermbox Bio, a biotech research and manufacturing company developing sustainable bio-based products through precision fermentation and advanced biotechnology tools and Dyadic Applied BioSolutions (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bio-industrial applications, today announced the commercial launch of animal-origin-free Recombinant DNase I (RNase-free). — Binod Daga, President BD & Strategic Partnerships, Fermbox Bio.
This represents the first commercialized product under the companies’ expanded collaboration announced in 2025 and ties into Fermbox Bio’s vision of building a robust biotech portfolio that translates advanced biological innovation into commercially viable, high-impact products.
Produced using Dyadic’s proprietary high-yield fungal microbial expression platforms and Fermbox Bio’s scale-up and biomanufacturing platforms, the Recombinant DNase I (RNase-free) is currently available in research grade with a cGMP -grade version in development to support biopharmaceutical manufacturing and cell and gene therapy applications. With its extensive process development, scale-up, and biomanufacturing capabilities, Fermbox Bio provides the execution backbone required to translate these recombinant products into scalable commercial supply.
Recombinant DNase I (RNase-free), is an endonuclease enzyme intended for nucleic-acid clean-up and sample preparation workflows where residual DNA can interfere with analytical results. Its RNase-free specification helps protect RNA integrity in sensitive RNA workflows used across biological research, biotechnology, and molecular diagnostics.
DNase I (RNase-free) is a strategically important enzyme and the first in a planned series of recombinant enzymes and proteins expected to be commercially introduced throughout 2026.
Planned pipeline products under the collaboration include recombinant α-lactalbumin, recombinant transferrin, recombinant human FGF-2, recombinant human lactoferrin, and additional recombinant proteins expressed using Dyadic’s fungal microbial platforms. The initial portfolio targets high-demand segments in cell culture media, media supplementation, and molecular biology reagents, supporting applications such as cell and gene therapy (CGT), vaccine and monoclonal antibody manufacturing, regenerative medicine, and advanced biologics development.
Under the collaboration framework, Dyadic provides its fungal microbial expression platforms, production strains, and development support, while Fermbox Bio leads downstream process development, scale-up, and manufacturing. The companies are aligned on global commercialization to serve research and biomanufacturing customers worldwide.
About Fermbox Bio:
Fermbox Bio is a biotechnology research and manufacturing company that develops and manufactures a broad portfolio of recombinant proteins, industrial enzymes, specialty ingredients, and other fermentation-enabled products for customers across life sciences, food and nutrition, and bio-industrial markets. With capabilities spanning process development, precision fermentation, scale-up, and biomanufacturing, Fermbox Bio supports the advancement of products from early development to scalable commercial supply.
For more information about Fermbox Bio, please visit www.fermbox.bio
About Dyadic Applied BioSolutions:
Dyadic Applied BioSolutions is a global biotechnology company that uses its proprietary microbial platforms to produce recombinant proteins that are sold or licensed to partners across the life sciences, food and nutrition, and bio-industrial markets. These high-quality proteins are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic’s C1 and Dapibus™ expression systems support flexible, cost-effective manufacturing, and are the foundation of a growing portfolio of commercial and partnered programs.
For more information about Dyadic, please visit www.dyadic.com
For samples and commercial enquiries, customers may contact Fermbox Bio or Dyadic.
Company contacts:
Dyadic Applied BioSolutions:
Joe Hazelton
President & COO
Email: info@dyadic.com
Fermbox Bio:
Mr. Binod Daga
President Business development & Strategic Partnerships
Email: Info@fermbox.bio
Binod Daga
Fermbox Bio Private Limited
info@fermbox.bio
Visit us on social media:
LinkedIn
YouTube
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
